IperionX Shares Under Pressure Amid Legal Scrutiny and Financial Restatement

IperionX shares crash after a major asset value correction triggers SEC investigations and reveals doubled losses, despite ongoing US defense contracts for titanium production.

A confluence of negative developments has rattled investors in IperionX, sending its share price into a steep decline. The stock plummeted by more than 22% in a single session on the Australian exchange this Monday. Over a three-day trading period, the cumulative loss reached approximately 43%.

Financial Restatement Triggers Legal Probes

The immediate catalyst was a significant financial correction disclosed on March 13. The company drastically revised the book value of its asset usage rights downward from an initial $21.4 million to just $3.75 million. This substantial discrepancy prompted a swift market reaction, with the equity shedding up to 16% of its value intraday.

The accounting adjustment has now drawn the attention of U.S. securities lawyers. Multiple law firms, including the Law Offices of Howard G. Smith and Glancy Prongay Wolke & Rotter LLP, announced investigations beginning March 16. These probes are examining whether IperionX or its executives may have violated federal securities laws.

Mounting Losses and Absent Revenue

Compounding the issue, the company released its half-year financial results for the period ending December 2025. The figures revealed a net loss that more than doubled to $34.8 million, compared to $16.2 million in the prior-year period. Notably, IperionX reported no revenue for the half. Research and development expenses were recorded at $10.8 million.

This combination of an accelerating cash burn rate and a continued lack of income has amplified market concerns regarding the company's execution risks and path to profitability.

Strategic Defense Contracts Provide a Counter-Narrative

Despite the acute financial and legal pressures, IperionX continues to advance its strategic expansion, backed by significant U.S. government support. The Department of Defense (DoD) has committed a total of $99 million to fund the company's titanium production initiatives. A portion of this funding, a $47.1 million package, has already been finalized. Furthermore, the Pentagon supplied IperionX with 290 tons of titanium scrap at no cost.

The stated objective is to scale annual production capacity from the current 200 tons to 1,400 tons by mid-2027.

Analyst Sentiment and Macroeconomic Headwinds

Following the restatement, analyst firm B. Riley adjusted its price target for IperionX downward from $58 to $52 on March 13. However, it maintained its "Buy" recommendation. The current consensus price target among analysts ranges from $51 to $71, which remains far above the stock's present trading level.

The future trajectory for IperionX is now heavily contingent on the outcome of the ongoing securities investigations and the company's ability to restore confidence in its financial reporting integrity. Adding to the challenging environment, the Reserve Bank of Australia increased its benchmark interest rate by 25 basis points to 4.10% on Tuesday, creating a less favorable financing climate for a pre-revenue enterprise.